Biosergen has got off to a successful start in India where patient studies are ongoing.
Biosergen has together with Indian Alkem initiated patient studies with its drug candidate BSG005 for fungal diseases.
Biosergen will conduct a new phase 1b study in patients with invasive fungal infections with its drug candidate BSG005.
Carlsquare Equity Research has published a research update following the Q2 2023 report.
Biosergen, som utvecklar ett läkemedel för behandling av invasiva svampsjukdomar, har framgångsrikt slutfört fas 1-studier i mars.
Mangold Insight initiate coverage of the biotechnology company Biosergen with a buy recommendation and a price target of SEK 2.
